Partners

Rondaxe has also formed partnerships with  exciting companies in the pharmaceutical arena.

Rondaxe and TGen Drug Development (TD2) have formed a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients.

Rondaxe has partnered with Thomson Reuters Science to provide business solutions and analysis in the Generics and API Intelligence area.

Rondaxe has entered into an agreement with Oncoholdings to provide services for the development of promising preclinical and early clinical anti-cancer agents.

Rondaxe has formed a strategic alliance with Alvarez & Marsal’s Healthcare Industry Group to provide manufacturing, supply chain and compliance services to the pharmaceutical industry.

Testimonials

“Rondaxe provided comprehensive support to our CMC efforts on XL-119. They took responsibility for the delivery of our Phase III clinical supplies, which were delivered on time and allowed our company to realize a substantial milestone payment.”

JoAnn Wilson, Ph.D.
Vice President Technology Development,
Exelixis

“Rondaxe provided invaluable CMC support to myself and my team, and was instrumental in the successful out-licensing of our lead product, STA-4783.”

Lijun Sun, Ph.D.
Vice President Chemistry
SYNTA Pharmaceuticals

“Rondaxe’s support has been critical to ARIAD in the success of the products we have under development.  Rondaxe’s experience in drug development has been an enabling asset for ARIAD, which we will continue to draw upon to further ARIAD’s success going forward.”

Sr. Director
Manufacturing;
ARIAD Pharmaceuticals, Inc.